focus -WSS

focus

author：knowledge 2025-09-30 18:59:44 - browse：735

Illustration oh researchers look up at a blister pill pac. Part of the blister pack is filled with pills, while the center shows a sketch of a brain. -- biotech coverage from STAT — Mike Reddy for STAT

One by one, the companies behind Zoloft, Prozac, and Paxil soured on psychiatry.

It was the early 2000s, and as America warmed to the sounds of Sisqó and Shakira, the world’s largest pharmaceutical firms were running out of ideas to treat mental illness. Their blockbuster treatments for depression and schizophrenia had reshaped society and made billions of dollars in the process, but the old cash cows were soon to go generic. Efforts to one-up the last generation of drugs mostly resulted in incremental changes to aging medicines. And when insurance companies balked at paying brand-name prices for extended-release generics, the money dried up and the industry moved out.

“The mindset of Big Pharma in those days was one pill for millions and millions of people,” said John LaMattina, who led Pfizer’s research division from 1999 to 2007. “Everyone was looking for the next Lipitor, and when that fizzled out, there was an exodus out of psychotherapeutic areas.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Tori Bowie and the unacceptable rates of Black maternal death

WSS

Heart disease in astronauts blamed on cosmic radiation

Physicians aren't 'burning out.' They're suffering from moral injury

FDA approval of Sarepta Duchenne genetic therapy gives me hope

United colonoscopy coverage change 'may cost lives,' doctors say

Drug repurposing or repositioning? The language matters

FDA approval of Sarepta Duchenne genetic therapy gives me hope

focus

focus

Wikipedia

Continuity nursing helped my family in our darkest PICU moments

New air purifier tech could be key to improving indoor air quality

Affirmative action in medical school literally saved lives

Walensky prepares to leave CDC — and Congress — behind

As demand for Covid shots wanes, Moderna seeks its next success

After affirmative action ruling, medical educators look to 'holistic review'

Trump demands the U.S. pay no more for drugs than other countries … again

The cancer drug shortage isn’t new — and neither are the solutions

In age of alternative facts, a scholarly course on calling out crap

Alnylam reports growth in sales of rare disease treatments

explore

FDA approves Sage Therapeutics’ rapid

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Group behind ProMed defends move to subscription

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

2 officers injured in shooting in Orlando, police say

Medicare proposal to cover medical devices draws a mixed reaction

hotspot

leisure time

hotspot

leisure time